Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES

Genetic Key Found for Cancer Patient's Treatment Failure

By Labmedica International staff writers
Posted on 26 Jan 2012
A gene variation has been found which can have a substantial effect on treatment responses in patients with a rare type of blood cancer.

The cluster of differentiation 95 (CD95) gene is one of the genes involved in controlling the death of cells in the body and having an abnormal version of the CD95 gene could also dictate survival rates for other cancer types like lymphoma, breast, and prostate cancer.

Scientists at Newcastle University (Newcastle upon Tyne, UK) used various molecular techniques to investigate the DNA and RNA of 654 patients enrolled in a leukemia trial. This included data from 231 people diagnosed with acute promyelocytic leukemia (APL).

The study revealed that patients with an abnormal variant of the CD95 gene have a substantially lower chance of survival, with just 64% of APL study participants with the variant surviving long-term, compared with 79% who have a normal version of the gene. Patients with the gene variant often failed to respond to treatment from the start and died from infection within weeks of diagnosis. Leukemia patients who fail to respond to chemotherapy are often susceptible to infections. It is difficult to predict which patients are at high risk of developing this life-threatening complication, and the scientists discovered that APL patients with the risk gene had a five times higher likelihood of dying from infection compared with patients with the more common version of the gene.

Molecular methods included in the study were the caspase-8 and caspase-3 cleavage assay using ligands from Enzo Life Sciences, (Farmingdale, NY, USA) and the Dual Luciferase Reporter Assay (Promega, Madison, WI, USA). James M. Allan, D.Phil., the senior author of the study, said, "By testing for the risk variant of the CD95 gene, we should now be able to help doctors identify those vulnerable patients at high risk of either not responding to chemotherapy or developing potentially fatal side effects from their treatment. These patients can then be treated differently to minimize the risk of a poor response." The study was published on January 12, 2012, in the journal Blood.

Related Links:

Newcastle University
Enzo Life Sciences
Promega




CELLAVISION AB
KARL HECHT GMBH & CO KG
MEDLAB Asia

Channels

Microbiology

view channel
Image: The Xpert MTB/RIF cartridge-based, fully automated molecular diagnostic test for tuberculosis (Photo courtesy of Cepheid).

Test Helps Physicians Remove Suspected TB Patients from Isolation

Tuberculosis (TB) is caused by the Mycobacterium tuberculosis complex (MTB-complex) and usually attacks the lungs and many people carry the MTB-complex bacteria without ever developing active disease.... Read more

Lab Tech.

view channel
Image:  The Flame – a miniature spectrometer for medical diagnostics, biotechnology, and life sciences, that brings flexible optical sensing power to laboratory and point-of-care instrument integration (Photo courtesy of Ocean Optics).

Next Generation Miniature Spectrometer Brings Flexibility to Diagnostics and Biotechnology

The mini spectrometer combines decades of pioneering miniature spectrometer design expertise with leading techniques, adding flexible optical sensing power to laboratory and point-of-care instrument integration.... Read more

Industry News

view channel
Image: Under a new partnership for liquid handling measurement automation, Artel will provide STRATEC’s innovative “Tholos” technology, which measures liquid and solid contents of 96- and 384-well microplates, under the name Artel “SDS” - Sample Detection System (Photo courtesy of Artel).

Artel Expands Portfolio with STRATEC Partnership for Automation Technology

Artel (Westbrook, Maine, USA), a leader in laboratory liquid handling measurement systems, and STRATEC Biomedical AG (Birkenfeld, Germany), a leader in automated systems for clinical diagnostics and biotechnology,... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
08 Mar 2015 - 12 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.